

13 September 2023

ASX Announcement

Island Pharmaceuticals granted key U.S. patent for ISLA-101

- Island's lead asset, ISLA-101 granted key patent from the United States Patent and Trademark Office (USPTO) covering methods of preventing or delaying the onset of the symptoms of dengue fever
- Patent underpins Island's drug repurposing strategy to rapidly and efficiently develop antiviral therapies with a key focus being mosquito borne viral diseases, such as dengue fever
- Around 390 million people are infected with dengue fever each year¹, representing a significant unmet need and opportunity.

MELBOURNE Australia, 13 September 2023: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; "Island"; "the Company") is pleased to announce that a key patent relating to the Company's lead drug candidate, ISLA-101, has been granted by the United States Patent and Trademark Office (USPTO).

The U.S. patent grant entitled "Method of Viral Inhibition" was issued under U.S. Patent No 11,752,116 and has an expiration date of 16 April 2034, subject to additional Patent Term Adjustment. Claims of the patent are directed to methods of preventing or delaying the onset of one or more symptoms of dengue fever, by administering ISLA-101 to the subject during a period of time in which the subject is at risk of exposure.

CEO of Island Pharmaceuticals, Dr David Foster said, *"We are very pleased to be granted this latest patent in the U.S. as it strengthens our growing intellectual property portfolio and further protects our lead program, in which ISLA-101 is being developed for use in dengue fever. With major outbreaks continuing to be reported around the world and the number of dengue fever cases increasing, the need for new approaches and treatments such as the ISLA-101 program is more imperative than ever. This makes IP protection fundamental to our success as we advance towards the commencement of clinical trials."*

Island has licensed the IP portfolio for ISLA-101, generated by Monash University. This latest U.S. patent adds to a strong IP portfolio that also includes Australia, Canada, Brazil, and Singapore.

Approved for release to the ASX by:

Dr Paul MacLeman
Executive Chairman
Island Pharmaceuticals Ltd
info@islandpharmaceuticals.com

¹ <https://www.worldmosquitoprogram.org/sites/default/files/2022-04/WMP%20dengue%20281%29.pdf>



Investors and media, for further information, please contact:

Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.